4-Hydroxyglutamate is a novel predictor of pre-eclampsia | Zendy

Ulla Sovio | Zendy; Nancy McBride | Zendy; Angela Wood | Zendy; Katya L Masconi | Zendy; Emma Cook | Zendy; Francesca Gaccioli | Zendy; D. Stephen CharnockJones | Zendy; Debbie A. Lawlor | Zendy; Gordon C. S. Smith | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

4-Hydroxyglutamate is a novel predictor of pre-eclampsia

Author(s) -

Ulla Sovio,

Nancy McBride,

Angela Wood,

Katya L Masconi,

Emma Cook,

Francesca Gaccioli,

D. Stephen CharnockJones,

Debbie A. Lawlor,

Gordon C. S. Smith

Publication year - 2019

Publication title -

international journal of epidemiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.406

H-Index - 208

eISSN - 1464-3685

pISSN - 0300-5771

DOI - 10.1093/ije/dyz098

Subject(s) - eclampsia , medicine , obstetrics , pregnancy , biology , genetics

Pre-term pre-eclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. A multi-centre randomized-controlled trial has shown that first-trimester screening followed by treatment of high-risk women with aspirin reduces the risk of pre-term pre-eclampsia. However, the biomarkers currently employed in risk prediction are only weakly associated with the outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research